{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:37:45Z","timestamp":1791380265188,"version":"4.3.3"},"reference-count":22,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,7,30]]},"DOI":"10.1536\/ihj.22-052","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:11:44Z","timestamp":1657750304000},"page":"669-677","source":"Crossref","is-referenced-by-count":49,"title":["Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome"],"prefix":"10.1536","volume":"63","author":[{"given":"Yan","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bor\u00e9n J, Chapman MJ, Krauss RM, <i>et al<\/i>. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41: 2313-30.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Serban MC, Colantonio LD, Manthripragada AD, <i>et al<\/i>. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol 2017; 69: 1386-95.","DOI":"10.1016\/j.jacc.2016.12.036"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Morrone D, Weintraub WS, Toth PP, <i>et al<\/i>. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-61.","DOI":"10.1016\/j.atherosclerosis.2012.02.016"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Reiner \u017d, De Backer G, Fras Z, <i>et al<\/i>. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis 2016; 246: 243-50.","DOI":"10.1016\/j.atherosclerosis.2016.01.018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Banach M, Penson PE, Vrablik M, <i>et al<\/i>. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res 2021; 166: 105499.","DOI":"10.1016\/j.phrs.2021.105499"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schwartz GG, Steg PG, Szarek M, <i>et al<\/i>. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097-107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bohula EA, Morrow DA, Giugliano RP, <i>et al<\/i>. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 2017; 69: 911-21.","DOI":"10.1016\/j.jacc.2016.11.070"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Liu YQ, Li DD, Chai M, <i>et al<\/i>. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). J Geriatr Cardiol 2021; 18: 261-70.","DOI":"10.22541\/au.159554641.10759874"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hadjiphilippou S, Ray KK. Evolocumab and clinical outcomes in patients with cardiovascular disease. J R Coll Physicians Edinb 2017; 47: 153-5.","DOI":"10.4997\/JRCPE.2017.212"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ridker PM, Revkin J, Amarenco P, <i>et al<\/i>. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 2017; 376: 1527-39.","DOI":"10.1056\/NEJMoa1701488"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gencer B, Marston NA, Im K, <i>et al<\/i>. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020; 396: 1637-43.","DOI":"10.1016\/S0140-6736(20)32332-1"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161-70.","DOI":"10.1016\/j.atherosclerosis.2015.12.018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mitsuda T, Uemura Y, Ishii H, <i>et al<\/i>. Lipoprotein (a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels 2016; 31: 1923-9.","DOI":"10.1007\/s00380-016-0823-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sumarjaya IDGD, Nadha IKB, Lestari AAW. High lipoprotein (a) levels as a predictor of major adverse cardiovascular events in hospitalized-acute myocardial infarction patients. Vasc Health Risk Manag 2020; 16: 125-32.","DOI":"10.2147\/VHRM.S233503"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bittner VA, Szarek M, Aylward PE, <i>et al<\/i>. Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020; 75: 133-44.","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rehberger Likozar A, Zavrtanik M, \u0160ebe\u0161tjen M. Lipoprotein (a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Ann Med 2020; 52: 162-77.","DOI":"10.1080\/07853890.2020.1775287"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein (a) levels. Eur Heart J 2020; 41: 2275-84.","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol 2015; 763: 38-47.","DOI":"10.1016\/j.ejphar.2015.03.099"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Koskinas KC, Siontis GCM, Piccolo R, <i>et al<\/i>. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2018; 39: 1172-80.","DOI":"10.1093\/eurheartj\/ehx566"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Squizzato A, Suter MB, Nerone M, <i>et al<\/i>. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med 2017; 12: 1043-53.","DOI":"10.1007\/s11739-017-1708-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ray KK, Colhoun HM, Szarek M, <i>et al<\/i>. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the Odyssey OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7: 618-28.","DOI":"10.1016\/S2213-8587(19)30158-5"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/4\/63_22-052\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T04:23:51Z","timestamp":1659155031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/4\/63_22-052\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-052","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"article-number":"22-052"}}